Teva Pharmaceutical Industries, a global generic drug maker, has acquired Cephalon.
Following the merger agreement between the parties, each share of Cephalon common stock has been converted into the right to receive $81.50 in cash.
Teva president and CEO Shlomo Yanai said the deal would strengthen their specialty pharmaceuticals business through diversification and expansion of their product.
"Our newly-expanded portfolio in CNS, Oncology, Respiratory and Women’s Health, along with our robust pipeline of more than 30 late-stage products truly cements our position as a leader in specialty pharma," Yanai added.
Teva expects the acquisition to be immediately accretive to Teva’s non-GAAP earnings per share and accretive to Teva’s GAAP earnings within the fourth quarter of closing.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData